These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 37973153)
1. Glucose metabolism-based signature predicts prognosis and immunotherapy strategies for colon adenocarcinoma. Bai Z; Yan C; Nie Y; Zeng Q; Xu L; Wang S; Chang D J Gene Med; 2024 Jan; 26(1):e3620. PubMed ID: 37973153 [TBL] [Abstract][Full Text] [Related]
2. Developing a RiskScore Model based on Angiogenesis-related lncRNAs for Colon Adenocarcinoma Prognostic Prediction. Li X; Lei J; Shi Y; Peng Z; Gong M; Shu X Curr Med Chem; 2024; 31(17):2449-2466. PubMed ID: 37961859 [TBL] [Abstract][Full Text] [Related]
3. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma. Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904 [No Abstract] [Full Text] [Related]
4. Transcriptomic correlates of cell cycle checkpoints with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response in colorectal adenocarcinoma. Wang H; Wang W; Wang Z; Li X Front Immunol; 2023; 14():1291859. PubMed ID: 38143740 [TBL] [Abstract][Full Text] [Related]
5. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma. Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y Front Immunol; 2022; 13():1038927. PubMed ID: 36451813 [TBL] [Abstract][Full Text] [Related]
6. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma. Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794 [TBL] [Abstract][Full Text] [Related]
7. Identification of a Four-Gene Metabolic Signature to Evaluate the Prognosis of Colon Adenocarcinoma Patients. Zheng Y; Wu R; Wang X; Yin C Front Public Health; 2022; 10():860381. PubMed ID: 35462848 [TBL] [Abstract][Full Text] [Related]
8. Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma. Xiao J; Wang X; Liu Y; Liu X; Yi J; Hu J Front Immunol; 2022; 13():881359. PubMed ID: 35911752 [TBL] [Abstract][Full Text] [Related]
9. Metabolism-related lncRNAs signature to predict the prognosis of colon adenocarcinoma. Sun Y; Liu B; Xiao B; Jiang X; Xiang JJ; Xie J; Hu XM Cancer Med; 2023 Mar; 12(5):5994-6008. PubMed ID: 36366731 [TBL] [Abstract][Full Text] [Related]
10. Predictive Models for Colon Adenocarcinoma Diagnosis, Prognosis, and Immune Microenvironment Based on 2 Hypoxia-Related Genes: KDM3A and ENO3. Kong C; Zheng L; Fang S; Chen M; Lin G; Qiu R; Zhao Z; Chen W; Song J; Yang Y; Ji J Technol Cancer Res Treat; 2023; 22():15330338231195494. PubMed ID: 37650153 [No Abstract] [Full Text] [Related]
11. Development of a 5-mRNAsi-related gene signature to predict the prognosis of colon adenocarcinoma. Huang H; Lu L; Li Y; Chen X; Li M; Yang M; Huang X PeerJ; 2023; 11():e16477. PubMed ID: 38025763 [TBL] [Abstract][Full Text] [Related]
12. Identification of sixteen metabolic genes as potential biomarkers for colon adenocarcinoma. Zhao F; Liu Y; Gu X; Zhang B; Song C; Cui B J BUON; 2021; 26(4):1252-1259. PubMed ID: 34564978 [TBL] [Abstract][Full Text] [Related]
13. A Risk Model for Prognosis and Treatment Response Prediction in Colon Adenocarcinoma Based on Genes Associated with the Characteristics of the Epithelial-Mesenchymal Transition. Huang H; Li T; Meng Z; Zhang X; Jiang S; Suo M; Li N Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686013 [TBL] [Abstract][Full Text] [Related]
14. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma. Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X Front Oncol; 2023; 13():1182434. PubMed ID: 37346073 [TBL] [Abstract][Full Text] [Related]
15. Based on cuproptosis-related lncRNAs, a novel prognostic signature for colon adenocarcinoma prognosis, immunotherapy, and chemotherapy response. Li C; Zhang K; Gong Y; Wu Q; Zhang Y; Dong Y; Li D; Wang Z Front Pharmacol; 2023; 14():1200054. PubMed ID: 37377924 [No Abstract] [Full Text] [Related]
16. A novel enterocyte-related 4-gene signature for predicting prognosis in colon adenocarcinoma. Cheng X; Wei Y; Fu Y; Li J; Han L Front Immunol; 2022; 13():1052182. PubMed ID: 36532007 [TBL] [Abstract][Full Text] [Related]
17. Identification of 9 Gene Signatures by WGCNA to Predict Prognosis for Colon Adenocarcinoma. Yang M; He H; Peng T; Lu Y; Yu J Comput Intell Neurosci; 2022; 2022():8598046. PubMed ID: 35392038 [TBL] [Abstract][Full Text] [Related]
18. In silico development and clinical validation of novel 8 gene signature based on lipid metabolism related genes in colon adenocarcinoma. Jiang C; Liu Y; Wen S; Xu C; Gu L Pharmacol Res; 2021 Jul; 169():105644. PubMed ID: 33940186 [TBL] [Abstract][Full Text] [Related]
19. Developing a prognosis and chemotherapy evaluating model for colon adenocarcinoma based on mitotic catastrophe-related genes. Liu Y; Zhao Y; Zhang S; Rong S; He S; Hua L; Wang X; Chen H Sci Rep; 2024 Jan; 14(1):1655. PubMed ID: 38238555 [TBL] [Abstract][Full Text] [Related]
20. A novel fatty acid metabolism-related gene signature predicts the prognosis, tumor immune properties, and immunotherapy response of colon adenocarcinoma patients. Liu L; Liang L; Mai G; Chen Y FASEB Bioadv; 2022 Sep; 4(9):585-601. PubMed ID: 36089979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]